Skip to Navigation
Skip to Main Content
Skip to Related Content

Advertisement

U.S. Markets closed

S&P 500
5,808.12
-1.74(-0.03%)
Dow 30
42,114.40
-259.96(-0.61%)
Nasdaq
18,518.61
+103.12(+0.56%)
Russell 2000
2,207.99
-10.93(-0.49%)
Crude Oil
71.69
+1.50(+2.14%)
Gold
2,760.80
+11.90(+0.43%)

BioNexus Gene Lab Corp. (BGLC)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Follow

Visitors trend2W10W9M

0.3750

-0.0130

(-3.35%)

At close: 04:00PM EDT

0.3800

+0.00

(+1.33%)

After hours:

07:27PM EDT

Currency in USD

Valuation Measures⁴

Market Cap (intraday)	6.74M
Enterprise Value	1.56M
Trailing P/E	N/A
Forward P/E	N/A
PEG Ratio (5 yr expected)	N/A
Price/Sales (ttm)	0.72
Price/Book (mrq)	0.71
Enterprise Value/Revenue	0.17
Enterprise Value/EBITDA	629.53

Trading Information

Stock Price History

Beta (5Y Monthly)	1.84
52-Week Change ³	N/A
S&P500 52-Week Change ³	N/A
52 Week High ³	3.3900
52 Week Low ³	0.3100
50-Day Moving Average ³	0.4121
200-Day Moving Average ³	0.5404

Share Statistics

Avg Vol (3 month) ³	373.6k
Avg Vol (10 day) ³	67.22k
Shares Outstanding ⁵	17.97M
Implied Shares Outstanding ⁶	N/A
Float ⁸	13.78M
% Held by Insiders ¹	43.72%
% Held by Institutions ¹	0.37%
Shares Short (Oct 15, 2024) ⁴	101.61k
Short Ratio (Oct 15, 2024) ⁴	0.6
Short % of Float (Oct 15, 2024) ⁴	0.58%
Short % of Shares Outstanding (Oct 15, 2024) ⁴	0.57%
Shares Short (prior month Sep 13, 2024) ⁴	852.15k

Dividends & Splits

Forward Annual Dividend Rate ⁴	N/A
Forward Annual Dividend Yield ⁴	N/A
Trailing Annual Dividend Rate ³	0.00
Trailing Annual Dividend Yield ³	0.00%
5 Year Average Dividend Yield ⁴	N/A
Payout Ratio ⁴	0.00%
Dividend Date ³	N/A
Ex-Dividend Date ⁴	N/A
Last Split Factor ²	N/A
Last Split Date ³	N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends	Dec 31, 2023
Most Recent Quarter (mrq)	Jun 30, 2024

Profitability

Profit Margin	-24.01%
Operating Margin (ttm)	13.12%

Management Effectiveness

Return on Assets (ttm)	-10.11%
Return on Equity (ttm)	-28.44%

Income Statement

Revenue (ttm)	9.18M
Revenue Per Share (ttm)	0.53
Quarterly Revenue Growth (yoy)	-23.10%
Gross Profit (ttm)	N/A
EBITDA	-1.46M
Net Income Avi to Common (ttm)	-2.21M
Diluted EPS (ttm)	-0.1500
Quarterly Earnings Growth (yoy)	N/A

Balance Sheet

Total Cash (mrq)	5.41M
Total Cash Per Share (mrq)	0.3
Total Debt (mrq)	451.45k
Total Debt/Equity (mrq)	4.73
Current Ratio (mrq)	5.61
Book Value Per Share (mrq)	0.54

Cash Flow Statement

Operating Cash Flow (ttm)	-1.87M
Levered Free Cash Flow (ttm)	-190.55k